Pittenger C

Mystical but not challenging experiences predict symptom improvement after psilocybin for treatment-resistant OCD.

Shnayder S, Agin-Liebes G, Hubert TJ +5

Who Is Reached by Supervised Psilocybin Services? Oregon Services Versus National Psilocybin Use

Costa GPA, Riggione C, Pittenger C +1

Surrender, disidentification, and reappraisal: a qualitative comparison of psilocybin responders and non-responders in treatment-resistant OCD.

Agin-Liebes G, Shnayder S, Fram G +6

α<sub>2</sub>-Adrenergic receptor modulates 5-HT<sub>2A</sub>-mediated behavioral effects of MDMA and psilocybin in mice.

Rosado AF, Yu AL, Yang JH +13

Enhancing cGMP signaling with psilocybin reduces head twitch and restructures the synaptic proteome while maintaining antidepressant response

Floris G, Jefferson SJ, Rondeau J +7

PreprintMDMA

MDMA enhances prefrontal plasticity and representational drift during fear extinction

Geva N, Jefferson SJ, Krishnamurthy E +7

Mystical but Not Challenging Experiences Predict Symptom Improvement After Psilocybin for Treatment-Resistant OCD

Shnayder S, Agin-Liebes G, Hubert T +5

Psilocybin for Treatment-Resistant OCD: A Randomized Controlled Trial

Kelmendi B, Adams T, Ching THW +16

Acute and post-dosing effects of single-dose psilocybin for obsessive-compulsive disorder in a randomized, double-blind, placebo-controlled trial: an interpretative phenomenological analysis.

Ching THW, Stahnke B, Shnayder S +22

Europe PMC2025

ArticleKetamine

The contribution of psychotherapy in potential therapeutic effects of psychedelics for treatment of opioid use disorder.

Nia AB, Farahmand Y, Griffith G +4

Europe PMC2025

Mechanisms of therapeutic change after psychedelic treatment in OCD.

Maloney G, Ching T, Kichuk SA +2

Europe PMC2024

Corrigendum: Safety, feasibility, tolerability, and clinical effects of repeated psilocybin dosing combined with non-directive support in the treatment of obsessive-compulsive disorder: protocol for a randomized, waitlist-controlled trial with blinded ratings.

Ching THW, Amoroso L, Bohner C +16

Europe PMC2024

Safety, feasibility, tolerability, and clinical effects of repeated psilocybin dosing combined with non-directive support in the treatment of obsessive-compulsive disorder: protocol for a randomized, waitlist-controlled trial with blinded ratings.

Ching THW, Amoroso L, Bohner C +15

ArticlePsychedelics

What Is in a Name? The Many Meanings of "Psychedelic".

O'Donnell KC, Roberts DE, Ching THW +8

Safety, tolerability, and clinical and neural effects of single-dose psilocybin in obsessive-compulsive disorder: protocol for a randomized, double-blind, placebo-controlled, non-crossover trial.

Ching THW, Grazioplene R, Bohner C +14

ArticleDMT

5-MeO-DMT modifies innate behaviors and promotes structural neural plasticity in mice.

Jefferson SJ, Gregg I, Dibbs M +10

Yale Program for Psychedelic Science (YPPS) Manual for Psilocybin Combined with Non-Directive Support in the Treatment of OCD

Ching THW, Grazioplene R, Pittenger C +1

ArticleMDMA

Methylone, a rapid acting entactogen with robust anxiolytic and antidepressant-like activity.

Warner-Schmidt J, Pittenger C, Stogniew M +3

Single-dose psilocybin for treatment-resistant obsessive-compulsive disorder: A case report.

Kelmendi B, Kichuk SA, DePalmer G +4

PreprintDMT

5-MeO-DMT modifies innate behaviors and promotes structural neural plasticity in mice

Jefferson SJ, Gregg I, Dibbs M +8

Yale Program for Psychedelic Science (YPPS) Manual for Psilocybin-OCD Session Monitors for Protocol HIC: 2000020355

Ching THW, Kichuk S, DePalmer G +2

ArticlePsychedelics

Psychedelics.

Kelmendi B, Kaye AP, Pittenger C +1